L2

General Information


DRACP ID  DRACP00054

Peptide Name   L2

Sequence  PAWFKARRWAWRMKKLAA

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Meth A Mouse fibrosarcoma Sarcoma IC50=144 µM MTT assay 4 h 1
MT-1 Human mammary carcinoma Carcinoma IC50>254 µM MTT assay 4 h 1
HT-29 Colon adenocarcinoma Carcinoma IC50>440 µM MTT assay 4 h 1

Hemolytic Activity  Human red blood cells: EC50>440 µM

Normal (non-cancerous) Cytotoxicity  Fibroblas: IC50>440 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00054

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C109H165N33O19S

Absent amino acids  CDEGHINQSTVY

Common amino acids  A

Mass  257719

Pl  12.82

Basic residues  6

Acidic residues  0

Hydrophobic residues  10

Net charge  6

Boman Index  -3512

Hydrophobicity  -66.67

Aliphatic Index  49.44

Half Life 
  Mammalian: >20 hour
  Yeast: >20 hour
  E.coli: ?

Extinction Coefficient cystines  16500

Absorbance 280nm  970.59

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 12366526

Title  Enhanced antitumor activity and selectivity of lactoferrin-derived peptides

Doi 10.1034/j.1399-3011.2002.21008.x

Year  2002

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.